FY2024 Earnings Estimate for TCRX Issued By Lifesci Capital

TScan Therapeutics, Inc. (NASDAQ:TCRX) – Investment analysts at Lifesci Capital lowered their FY2024 earnings per share (EPS) estimates for TScan Therapeutics in a note issued to investors on Tuesday, November 12th. Lifesci Capital analyst S. Slutsky now expects that the company will post earnings of ($1.08) per share for the year, down from their previous estimate of ($1.07). The consensus estimate for TScan Therapeutics’ current full-year earnings is ($1.17) per share. Lifesci Capital also issued estimates for TScan Therapeutics’ FY2025 earnings at ($1.08) EPS.

TCRX has been the subject of several other research reports. Needham & Company LLC restated a “buy” rating and issued a $11.00 price target on shares of TScan Therapeutics in a research note on Tuesday. Wedbush reiterated an “outperform” rating and set a $10.00 price objective on shares of TScan Therapeutics in a research report on Tuesday, November 5th. Finally, HC Wainwright reissued a “buy” rating and set a $15.00 price target on shares of TScan Therapeutics in a report on Friday. Five analysts have rated the stock with a buy rating, Based on data from MarketBeat, the company currently has an average rating of “Buy” and an average price target of $12.00.

TScan Therapeutics Stock Down 8.5 %

TCRX stock opened at $4.41 on Friday. TScan Therapeutics has a 1-year low of $3.73 and a 1-year high of $9.69. The business has a fifty day moving average price of $5.31 and a 200-day moving average price of $6.49. The company has a debt-to-equity ratio of 0.13, a current ratio of 9.56 and a quick ratio of 7.77. The stock has a market capitalization of $233.62 million, a P/E ratio of -4.16 and a beta of 0.79.

Hedge Funds Weigh In On TScan Therapeutics

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in the company. Barclays PLC boosted its stake in TScan Therapeutics by 341.1% during the third quarter. Barclays PLC now owns 58,067 shares of the company’s stock valued at $289,000 after buying an additional 44,903 shares during the last quarter. XTX Topco Ltd purchased a new stake in TScan Therapeutics during the third quarter valued at approximately $112,000. Wellington Management Group LLP raised its position in TScan Therapeutics by 38.9% during the third quarter. Wellington Management Group LLP now owns 126,345 shares of the company’s stock valued at $629,000 after purchasing an additional 35,404 shares during the period. State Street Corp raised its position in TScan Therapeutics by 24.4% during the third quarter. State Street Corp now owns 756,499 shares of the company’s stock valued at $3,767,000 after purchasing an additional 148,414 shares during the period. Finally, Stifel Financial Corp raised its position in TScan Therapeutics by 3.9% during the third quarter. Stifel Financial Corp now owns 99,133 shares of the company’s stock valued at $494,000 after purchasing an additional 3,733 shares during the period. 82.83% of the stock is owned by institutional investors.

Insider Transactions at TScan Therapeutics

In other TScan Therapeutics news, Director Barbara Klencke acquired 5,000 shares of the company’s stock in a transaction dated Monday, August 26th. The stock was purchased at an average price of $5.53 per share, with a total value of $27,650.00. Following the completion of the purchase, the director now directly owns 40,000 shares in the company, valued at approximately $221,200. The trade was a 14.29 % increase in their position. The acquisition was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, insider Zoran Zdraveski sold 164,686 shares of the stock in a transaction that occurred on Friday, August 23rd. The shares were sold at an average price of $5.78, for a total value of $951,885.08. Following the transaction, the insider now directly owns 4,716 shares of the company’s stock, valued at approximately $27,258.48. The trade was a 97.22 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders acquired a total of 15,000 shares of company stock valued at $82,550 over the last 90 days. Company insiders own 2.76% of the company’s stock.

About TScan Therapeutics

TScan Therapeutics, Inc, a clinical-stage biopharmaceutical company, develops T cell receptor-engineered T cell (TCR-T) therapies for the treatment of patients with cancer in the United States. The company's lead product candidates include TSC-100 and TSC-101 that is in Phase I clinical trial for the treatment of patients with hematologic malignancies to eliminate residual disease and prevent relapse after allogeneic hematopoietic cell transplantation.